Autoantibody Biomarker Discovery
Autoantibodies are produced by the immune system and have been identified as important biomarkers in cancer, auto-immune and neurodegenerative diseases. Its appearance may precede disease symptoms by many years and due to the inherent amplification of the immune system, they are readily detectable. Their unique potential for pre-symptomatic and early diagnosis of disease makes autoantibodies effective tools for biomarker discovery.
Autoantibodies can assist in disease prediction and prognosis, which translates to more effective antibody-based therapeutics once combined with novel bioinformatics methods and algorithms. This results in an increased likelihood of the development of new tests that offer the probability of earlier diagnosis, improved disease prediction and stratification of patients.
For the purposes of this application, we recommend the usage of the Standard Immunome protein array for exploratory purposes. Custom Array slides are also useful if you need any additional types or isoforms of certain proteins on the array.
Adverse Drug Reaction (ADR) Prediction
Immunotherapies are changing the outlook for many cancer patients. For instance, inhibition of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed death 1 (PD1) immune checkpoints has been proven to activate the immune system. The administration of inhibitors targeting these checkpoints, both individually, and in combination, have shown promising results for the treatment of melanoma and non-small cell lung cancer.
However, the complex and diverse nature of cancers mean that the effectiveness of the treatments varies both by type of cancer, and by patient. In fact, some patients, depending on their physiological makeup, may suffer from immune-related adverse events (irAE) from these therapies, which can include autoimmune responses. Therefore, profiling immunotherapy-related immuno-toxicity in cancer patients could serve as a tool to better predict the correct dosage and combination, as well as patient’s response to treatment. This could help lessen the adverse effect of irAE in immunotherapies, while maintaining its’ benefits.
For this application, we recommend the usage of the Standard Immunome protein array to examine the autoantibody signatures of patients. However, it can be modified to suit your needs if any additional types or isoforms of certain proteins would be needed in the array.
Infectious Diseases Diagnostics
Rapid, high-throughput and sensitive diagnosis of infectious diseases by using custom arrays spotted with viral and bacterial proteins. Sengenics’ Immunome protein array platform can be customised to include viral/bacterial/parasitic antigens that can be used against human samples in order to screen infections. For the purposes of this application, we recommend the usage of the Custom Array service as described in our Solutions page.